Evista

NDA 22042, held by Lilly. Raloxifene Hydrochloride.

As of Nov 14, 2026, NDA 22042 (Evista), held by Lilly, was first approved by FDA on Sep 13, 2007, with 0 approved supplements and 0 published complete response letters.

• First approved: Sep 13, 2007
• Review: Standard
• Supplements approved: 0
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters